HypErsensitiVity PneumonITis: DiseAse Progression Characterization (EVITA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04961944 |
Recruitment Status :
Recruiting
First Posted : July 14, 2021
Last Update Posted : June 29, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Hypersensitivity Pneumonitis | Other: Disease assessment |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 150 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 24 Months |
Official Title: | HypErsensitiVity PneumonITis: DiseAse Progression Characterization. An International Multicentric Prospective Observational Study |
Actual Study Start Date : | June 20, 2022 |
Estimated Primary Completion Date : | December 1, 2025 |
Estimated Study Completion Date : | March 1, 2026 |
Group/Cohort | Intervention/treatment |
---|---|
Hypersensitivity pneumonitis
see elegibility criteria
|
Other: Disease assessment
A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed. The association between endotypes and disease progression will be tested. Other Names:
|
- Variation in Forced Vital Capacity (FVC) as a continuous variable [ Time Frame: 24 months ]
- Variation in Computed Tomography Lung Densitometry [ Time Frame: 24 months ]
- Time to death or lung transplantation [ Time Frame: 24 months ]
- Acute exacerbation rate [ Time Frame: 24 months ]
- King´s Brief Interstitial Lung Disease Questionnaire (K-BILD) [ Time Frame: 24 months ]
- Proportion of patients varying FVC >= 10% [ Time Frame: 24 months ]
- Variation in meters walked measured by the 6MWT [ Time Frame: 24 months ]
- Variation in the ratio dessaturation/meters-walked measured by 6MWT [ Time Frame: 24 months ]
- Variation in the dyspnea scores on mMRC scale [ Time Frame: 24 months ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult outpatient subjects (18 years old or older) that fulfill the 2020 ATS/JRS/ALAT diagnostic criteria of HP of at least moderate confidence (70% confidence or more).
- Willingness to undergo the evaluations proposed in this protocol
- HP diagnosis within the last 24 months
- Presence of radiological or histological fibrosis:
4.a. Radiological fibrosis consists of unequivocal fine or coarse reticulation with architectural lung distortion and/or traction bronchiectasis and/or honeycomb.
4.b. Unequivocal histopathological fibrosis evidenced on lung specimens
Exclusion Criteria:
- Pregnancy
- Presence of established connective tissue disease
- Severe comorbidity impacting on the respiratory system as judged by the attending physician (ex. congestive heart failure, neoplasm, post-COVID-19 sequelae)
- Use of supplemental oxygen at rest
- Dyspnea mMRC 4 (too breathless to leave the house or breathless when dressing or undressing)
- Unequivocal emphysematous pattern of HP on HRCT
- Unequivocal pleuro-parenchymal fibroelastosis on the HRCT
- Significant pulmonary arterial hypertension:
8.a. Signs of right ventricular failure by echodopplercardiogram or 8.b. Cardiac index < 2L/min/m2 or right heart catheterism
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04961944
Contact: Leticia Kawano-Dourado (PI), MD | +551130536611 | ldourado@hcor.com.br | |
Contact: Samara Pinheiro (Project Manager) | scgomes@hcor.com.br |
Argentina | |
Hospital Prov de Tórax Dr. A. Cetrángolo | Active, not recruiting |
Bueno Aires, Argentina | |
Instituto de Rehabilitacion Psicofisica | Active, not recruiting |
Buenos Aires, Argentina | |
University of Buenos Aires | Active, not recruiting |
Buenos Aires, Argentina | |
Brazil | |
LABOX - Federal University of Santa Catarina | Active, not recruiting |
Santa Catarina, SC, Brazil | |
LAPOGE - Federal University of Santa Catarina | Active, not recruiting |
Santa Catarina, SC, Brazil | |
University Hospital HU Professor Polydoro - Federal University of Santa Catarina | Active, not recruiting |
Florianópolis, Brazil | |
Centro EDUMED | Active, not recruiting |
Paraná, Brazil | |
Hospital do Servidor Estadual de Sao Paulo (IAMPSE) | Recruiting |
Sao Paulo, Brazil | |
Contact: Silvia Rodrigues, MD | |
InCor - Medical School of the University of Sao Paulo | Not yet recruiting |
Sao Paulo, Brazil | |
Contact: Fabio Arimura, MD | |
Chile | |
Instituto Nacional del Tórax | Not yet recruiting |
Santiago, Chile | |
Contact: Felipe Reyes, MD | |
Contact: Matias Florenzano, MD |
Principal Investigator: | Leticia Kawano Dourado, MD | HCOR Research Institute, Hospital do Coracao, São Paulo, Brazil | |
Study Chair: | Prof. Alexandra Latini, PhD | Federal University of Santa Catarina |
Responsible Party: | Hospital do Coracao |
ClinicalTrials.gov Identifier: | NCT04961944 |
Other Study ID Numbers: |
EVITA BI 1199-0430 |
First Posted: | July 14, 2021 Key Record Dates |
Last Update Posted: | June 29, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
hypersensitivity pneumonitis pulmonary fibrosis interstitial lung disease |
Pneumonia Alveolitis, Extrinsic Allergic Hypersensitivity Disease Progression Immune System Diseases Disease Attributes Pathologic Processes |
Respiratory Tract Infections Infections Lung Diseases Respiratory Tract Diseases Lung Diseases, Interstitial Respiratory Hypersensitivity Hypersensitivity, Immediate |